Short- and long-term survival has improved after radical cystectomy for bladder cancer in Québec during the years 2000-2015.


Journal

Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643

Informations de publication

Date de publication:
Jun 2019
Historique:
received: 22 01 2019
revised: 21 02 2019
accepted: 03 03 2019
pubmed: 29 3 2019
medline: 15 6 2019
entrez: 29 3 2019
Statut: ppublish

Résumé

We evaluated the short- and long-term outcome in bladder cancer (BC) patients treated with radical cystectomy (RC) in Québec (Canada). Data were collected from provincial registries on all BC patients who underwent RC in Québec province in 2000-2015. Outcomes were hospitalization rates and survival. Survival analyses were conducted using log-rank tests and Cox proportional hazards models. In total, 4450 patients were included in our analysis. RC was increasingly conducted by higher-volume surgeons in larger, higher-volume, academic hospitals. Comparing patients treated in 2010-2015 to 2000-2009, recently treated patients had shorter postoperative hospital stays (absolute difference, 0.9 days, P < 0.001) but also a higher readmission rate (25.0% vs 21.1% in the 30 days following discharge, P = 0.003). Overall (5-year rates 50.9% vs 42.7%, P < 0.001) and BC-specific survival (61.3% vs 55.5%, P < 0.001) had significantly improved. In multivariable analyses, overall survival was significantly better in recently treated patients (hazard ratio [HR], 0.66; 95% confidence interval [CI], 0.60-0.73), younger patients (HR, 1.16; 95% CI, 1.14-1.19), patients residing closer to the hospital (HR, 1.03; 95% CI, 1.01-1.06), and patients treated by high-volume surgeons (HR, 0.88; 95% CI, 0.82-0.94). Survival in BC patients after RC has improved in recent years. Other predictors for survival are younger age, shorter distance between patients' residences and hospitals, and higher surgeon's RC loads.

Sections du résumé

BACKGROUND AND OBJECTIVES OBJECTIVE
We evaluated the short- and long-term outcome in bladder cancer (BC) patients treated with radical cystectomy (RC) in Québec (Canada).
METHODS METHODS
Data were collected from provincial registries on all BC patients who underwent RC in Québec province in 2000-2015. Outcomes were hospitalization rates and survival. Survival analyses were conducted using log-rank tests and Cox proportional hazards models.
RESULTS RESULTS
In total, 4450 patients were included in our analysis. RC was increasingly conducted by higher-volume surgeons in larger, higher-volume, academic hospitals. Comparing patients treated in 2010-2015 to 2000-2009, recently treated patients had shorter postoperative hospital stays (absolute difference, 0.9 days, P < 0.001) but also a higher readmission rate (25.0% vs 21.1% in the 30 days following discharge, P = 0.003). Overall (5-year rates 50.9% vs 42.7%, P < 0.001) and BC-specific survival (61.3% vs 55.5%, P < 0.001) had significantly improved. In multivariable analyses, overall survival was significantly better in recently treated patients (hazard ratio [HR], 0.66; 95% confidence interval [CI], 0.60-0.73), younger patients (HR, 1.16; 95% CI, 1.14-1.19), patients residing closer to the hospital (HR, 1.03; 95% CI, 1.01-1.06), and patients treated by high-volume surgeons (HR, 0.88; 95% CI, 0.82-0.94).
CONCLUSIONS CONCLUSIONS
Survival in BC patients after RC has improved in recent years. Other predictors for survival are younger age, shorter distance between patients' residences and hospitals, and higher surgeon's RC loads.

Identifiants

pubmed: 30919984
doi: 10.1002/jso.25456
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1135-1144

Subventions

Organisme : McGill University
ID : Richard Tomlinson Chair in Urology
Organisme : McGill University Health Center
Organisme : Canadian Institutes of Health Research
ID : Postdoctoral Fellowship Award
Pays : Canada

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Auteurs

Michel D Wissing (MD)

Department of Surgery, McGill University Health Centre, Montreal, Québec, Canada.
Department of Oncology, McGill University, Montreal, Québec, Canada.

Fabiano Santos (F)

Division of Technology and Innovation, International Development Research Centre, Ottawa, Ontario, Canada.

Ahmed S Zakaria (AS)

Department of Surgery, McGill University Health Centre, Montreal, Québec, Canada.

Ana O'Flaherty (A)

Department of Surgery, McGill University Health Centre, Montreal, Québec, Canada.

Simon Tanguay (S)

Department of Surgery, McGill University Health Centre, Montreal, Québec, Canada.

Wassim Kassouf (W)

Department of Surgery, McGill University Health Centre, Montreal, Québec, Canada.

Armen G Aprikian (AG)

Department of Surgery, McGill University Health Centre, Montreal, Québec, Canada.
Department of Oncology, McGill University, Montreal, Québec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH